Company: AZN
Filing Date: 2025-04-29
Form Type: 6-K
Source: 0001654954-25-004737
Chunk: 8

Company: ASTRAZENECA PLC
Filing Date: 2025-04-29
Form: 6-K
Chunk 8
---
58 |                 9 | 15 |     |                                              |

Other Medicines

| Q1 2025$m | Total   
 Revenue |     |          % Change 
 Actual        CER |     |     |                                              |
| Nexium    |         | 233 |                -4 |   - |     | ∗Growth in Emerging Markets, generic erosion 
 elsewhere                                    |
| Others    |         |  39 |               -28 | -26 |     | ∗Generic erosion                             |

R&D progress

This section covers R&D events and milestones that have occurred since the prior results announcement on 6 February 2025, up to and including events on 28 April 2025. A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations. The Clinical Trials Appendix includes tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the pipeline.

Oncology

AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical congresses since the prior results announcement: the European Lung Cancer Congress 2025 and the American Association for Cancer Research Annual Meeting 2025. Across the two meetings, more than 100 abstracts were presented featuring 10 approved and potential new medicines including 14 oral presentations.

Calquence

| CHMP opinion 
 Europe       | ACE-LY-004     
 February 2025  
 New disclosure | ∗As monotherapy for relapsed or refractory                   
 mantle cell lymphoma.                                        |
| Approval     
 China        | ChangE         
 March 2025     
 New disclosure | ∗As monotherapy for the treatment of chronic                 
 lymphocytic leukaemia/small lymphocytic                      
 lymphoma.                                                    |
| CHMP opinion 
 Europe       | AMPLIFY        
 April 2025     
 New disclosure | ∗In combination with venetoclax with or                      
 without obinutuzumab is indicated for the treatment of adult 
 patients with previously untreated chronic lymphocytic       
 leukaemia.                                                   |

Enhertu

| Phase III readout | DESTINY-Gastric04 
 March 2025        
 New disclosure    | ∗Positive high-level results demonstrated                          
 thatEnherturesulted in a statistically significant and             
 clinically meaningful improvement in the primary endpoint of OS    
 compared to ramucirumab and paclitaxel in patients with